PDF(Pubmed)
Abstract：
Background: Diabetes is a rapidly growing global morbidity issue with high prevalence, and the associated dysglycemia leads to complications. Patients with type 2 diabetes mellitus (T2DM) often experience elevated anxiety levels, affecting their quality of life and diabetes management. This study investigated quercetin, a nutraceutical and potential senolytic with antioxidant activity, to detect its possible positive effect on the bio-clinical measurements and routine health of patients with T2DM. Methods: This prospective randomized controlled trial (RCT) investigated the clinical usefulness of quercetin in patients with T2DM receiving non-insulin medications. One hundred participants were stratified by age and sex (1:1) and randomized to control (n = 50) or intervention (n = 50) groups. The control received standard care only, while the intervention received 500 mg quercetin daily for 12 weeks, followed by an 8-week washout and a final consecutive 12-week supplementation period (total: 32 weeks), as adjunct to their usual care. Comprehensive health assessments, including blood analyses, were conducted at baseline and study termination. Quality of life and anxiety were assessed using the 36-item Short Form Health Survey (SF-36) and Short Anxiety Screening Test (SAST-10). Results: Eighty-eight patients with T2DM concluded the trial. Compared with the control, glycated hemoglobin (HbA1c) levels showed a significant decrease (Δ%-change: -4.0% vs. 0.1%, p = 0.011). Quercetin also significantly improved PiKo-6 readings (FEV1: 5.6% vs. -1.5%, p = 0.002), systolic blood pressure (-5.0% vs. -0.2%, p = 0.029), night-time sleep (11.6% vs. -7.3%, p < 0.001), anxiety levels (SAST-10) (-26.2% vs. 3.3%, p < 0.001), and quality of life (SF-36) (both physical and mental components, p < 0.001). Conclusions: Based on the current open-label study, quercetin appears to be a promising supplement for T2DM, providing lifestyle and care support. Further research is warranted to shift this potential from clinical usefulness and feasibility to multidisciplinary evidence.
摘要：
背景：糖尿病是一个迅速增长的全球发病率问题，患病率高，相关的血糖异常会导致并发症。2型糖尿病（T2DM）患者经常经历焦虑水平升高，影响他们的生活质量和糖尿病管理。这项研究调查了槲皮素，一种具有抗氧化活性的营养食品和潜在的抗衰老剂，检测其对T2DM患者的生物临床测量和常规健康可能的积极影响。方法：这项前瞻性随机对照试验（RCT）研究槲皮素在接受非胰岛素治疗的T2DM患者中的临床应用。100名参与者按年龄和性别（1：1）进行分层，并随机分为对照组（n=50）或干预组（n=50）。对照组只接受标准护理，而干预措施每天接受500毫克槲皮素，持续12周，随后是8周的冲洗和最后连续12周的补充期（总计：32周），作为他们日常护理的辅助。全面的健康评估，包括血液分析,在基线和研究终止时进行。使用36项简短形式健康调查（SF-36）和短期焦虑筛查测试（SAST-10）评估生活质量和焦虑。结果：88例T2DM患者完成试验。与对照相比，糖化血红蛋白（HbA1c）水平显着降低（Δ％变化：-4.0％vs.0.1%,p=0.011)。槲皮素也显着改善了PiKo-6的读数（FEV1：5.6％与-1.5%，p=0.002),收缩压（-5.0%vs.-0.2%，p=0.029),夜间睡眠(11.6%与-7.3%，p<0.001)，焦虑水平（SAST-10）（-26.2%vs.3.3%,p<0.001)，和生活质量(SF-36)(包括身体和精神部分，p<0.001)。结论：基于目前的开放标签研究，槲皮素似乎是T2DM的一种有希望的补充剂，提供生活方式和护理支持。需要进一步的研究将这种潜力从临床有用性和可行性转变为多学科证据。
